These studies indicate variable neuropathology in LRRK2 mutation carriers, including typical Lewy bodies, tau pathology, or nigral degeneration without Lewy bodies. Suggests LRRK2 mutations may predict specific PD sequelae. The gene discussed is MAPT; the disease is Parkinson disease.